MARKET

RNAC

RNAC

Cartesian
NASDAQ
8.97
+0.45
+5.28%
Closed 17:38 12/15 EST
OPEN
8.53
PREV CLOSE
8.52
HIGH
9.23
LOW
8.43
VOLUME
291.05K
TURNOVER
0
52 WEEK HIGH
20.30
52 WEEK LOW
5.98
MARKET CAP
233.25M
P/E (TTM)
-4.5616
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAC last week (1208-1212)?
Weekly Report · 1d ago
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
TipRanks · 4d ago
Cartesian rebounds after insider purchase
Seeking Alpha · 6d ago
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance
NASDAQ · 12/09 05:04
Director’s Bold Move: Major Stock Purchase at Cartesian Therapeutics!
TipRanks · 12/09 02:01
Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc
Reuters · 12/08 21:07
Weekly Report: what happened at RNAC last week (1201-1205)?
Weekly Report · 12/08 09:22
Weekly Report: what happened at RNAC last week (1124-1128)?
Weekly Report · 12/01 09:21
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.